Business Context and Reporting Period
Company: Braskem S.A.
Filing Type: Form 6-K (Earnings Release)
Reporting Period: Fourth Quarter (4Q) and Full Year 2025
Release Date: March 27, 2026
Braskem, the largest resin producer in the Americas and global leader in biopolymers, reported results for 4Q25 amidst a prolonged global petrochemical downcycle. The period was characterized by geopolitical conflicts, tariff wars, and seasonal demand pressures. Significant regulatory developments included the establishment of the Special Sustainability Program for the Chemical Industry (PRESIQ) and an increase in the REIQ tax benefit.
Key Financial Metrics
| Metric | 4Q25 Value | Full Year 2025 Value |
|---|---|---|
| Consolidated Recurring EBITDA | US$ 109 million | Filing text does not provide a clear consolidated full-year value |
| Net Income (Loss) Attributable to Shareholders | Loss of US$ 1.9 billion | Loss of US$ 1.8 billion |
| Corporate Gross Debt | US$ 9.4 billion | US$ 9.4 billion (as of Dec 31, 2025) |
| Cash Position | US$ 2.1 billion | Filing text does not provide a clear full-year ending value |
| Adjusted Net Debt | US$ 7.5 billion | US$ 7.5 billion (as of Dec 31, 2025) |
| Corporate Leverage | 14.74x | Filing text does not provide a clear full-year value |
| Operational Cash Generation | R$ 71 million | Filing text does not provide a clear full-year value |
Segment Performance (4Q25)
- Brazil/South America: Recurring EBITDA of US$ 143 million (down 30% vs 3Q25). Utilization rate decreased 6 percentage points due to scheduled shutdowns and seasonality.
- United States & Europe: Recurring EBITDA of negative US$ 32 million. Utilization rate decreased 8 percentage points due to European plant shutdowns and inventory optimization.
- Mexico: Recurring EBITDA of US$ 11 million. Utilization rate increased 38 percentage points following maintenance normalization. Note: A US$ 272 million impairment loss was recorded in COGS but did not impact Recurring EBITDA.
Material Changes vs. Prior Period
- EBITDA Decline: Consolidated Recurring EBITDA fell 27% in USD compared to 3Q25, driven by lower international spreads for resins and chemicals, reduced sales volumes in Brazil, and higher idle/shutdown expenses.
- Net Loss: The 4Q25 net loss of US$ 1.9 billion was significantly higher than 3Q25, primarily due to a US$ 1.4 billion write-off of deferred tax assets (non-cash impact).
- Debt and Leverage: Corporate gross debt increased to US$ 9.4 billion following a US$ 1.0 billion drawdown from a stand-by facility in October 2025. Leverage rose to 14.74x.
- Alagoas Provision: The provision for the geological event in Alagoas decreased to R$ 3.5 billion (down 7% from 3Q25) due to payments, reclassifications, and reversals from updated cost estimates.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy
- 2026 Investments: Planned investments for Braskem (excluding Braskem Idesa and REIQ) are estimated at US$ 465 million, a 31% reduction from the historical six-year average.
- TransformaRio Project: Board approved a R$ 4.2 billion investment to expand ethane-based capacity in Rio de Janeiro by 220,000 tons/year, with completion expected by end of 2028.
- Regulatory Support: New laws (Law 15,294/25 and Complementary Law 228) provide tax incentives (PRESIQ and increased REIQ benefits) to defend the competitiveness of the Brazilian chemical industry.
Risks and Contingencies
- Braskem Idesa Distress: The Mexico subsidiary (Braskem Idesa) defaulted on interest payments in November 2025 and February 2026. Credit ratings were downgraded to 'D' (S&P) and 'RD' (Fitch). The subsidiary is exploring capital structure reorganization, potentially including Chapter 11 proceedings.
- Alagoas Geological Event: While the State Agreement provides a discharge from state-level damages, the Company faces ongoing administrative proceedings, potential new lawsuits, and uncertainty regarding future costs for cavity monitoring and environmental remediation.
- Market Conditions: Continued pressure from global oversupply, predatory dumping, and geopolitical instability affecting spreads and demand.
Investor Verification Checklist
- Braskem Idesa Solvency: Verify the status of negotiations with bondholders and the likelihood of a successful capital structure reorganization or bankruptcy filing.
- Deferred Tax Asset Write-off: Confirm the specific accounting treatment and future reversibility of the US$ 1.4 billion deferred tax asset write-off impacting the 4Q25 net loss.
- Alagoas Provision Adequacy: Assess the sensitivity of the R$ 3.5 billion provision to potential new legal claims or changes in the geological monitoring plan.
- Liquidity Position: Monitor the impact of the US$ 1.0 billion debt drawdown on future interest expenses and the company's ability to service US$ 9.4 billion in gross debt.
- Regulatory Implementation: Track the actual realization of tax benefits under the new PRESIQ and REIQ regimes to ensure projected cash flow improvements materialize.